



Oral Fluid Drug Test Cube Package Insert

Package insert for testing of the following drugs:

Amphetamine 50, Barbiturates 50, Benzodiazepine 10, Cocaine 20, Marijuana 12, Methadone 30, Methamphetamine 50, Morphine 15, Opiate 40, Propoxyphene 50 and Codeine 10.

For employment and insurance use.

For forensic use.

INTENDED USE & SUMMARY

The InstaCube Oral Fluid Drug Test Cube is intended for screening for the presence of drugs and their metabolites in oral fluid. For professional *in vitro* diagnostic use only.

The InstaCube Oral Fluid Drug Cube Test is a lateral flow chromatographic immunoassay for the qualitative detection of drugs and drug metabolites in oral fluid at the following cut-off concentrations:

Test	Calibrator	Cut-off (ng/mL)
Amphetamine (AMP)	d-Amphetamine	50
Barbiturate (BAR)	Secobarbital	50
Benzodiazepine (BZO)	Oxazepam	10
Cocaine (COC)	Benzoyllecgonine	20
Marijuana (THC)	11-nor- Δ^9 -THC-9 COOH	12
Methadone (MTD)	Methadone	30
Methamphetamine (MET)	D-Methamphetamine	50
Morphine (MOP)	Morphine	15
Opiates (OPI)	Morphine	40
Propoxyphene (PPX)	Propoxyphene	50
Codeine(COD)	codeine	10

This test will detect other related compounds, please refer to the Analytical Specificity table in this package insert.

AMP: Amphetamine is a sympathomimetic amine with therapeutic indications. The drug is often self-administered by nasal inhalation or oral ingestion.¹

BAR: Barbiturates are central nervous system depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence. Short acting Barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence.

Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

BZO: Benzodiazepines are central nervous system (CNS) depressants commonly prescribed for the short-term treatment of anxiety and insomnia. In general, benzodiazepines act as hypnotics in high doses, as anxiolytics in moderate doses and as sedatives in low doses. The use of benzodiazepines can result in drowsiness and confusion. Psychological and physical dependence on benzodiazepines can develop if high doses of the drug are given over a prolonged period. Benzodiazepines are taken orally or by intramuscular or intravenous injection, and are extensively oxidized in the liver to metabolites. Benzodiazepines can be detected in oral fluid after use.

COC: Cocaine is a potent central nervous system (CNS) stimulant and a local anesthetic derived from the coca plant (erythroxylum coca).¹

THC: Tetrahydrocannabinol, the active ingredient in the marijuana plant (cannabis sativa), is detectable in oral fluid shortly after use. The detection of the drug is thought to be primarily due to the direct exposure of the drug to the mouth (oral and smoking administrations) and the subsequent sequestering of the drug in the buccal cavity.²

MTD: Methadone is a synthetic analgesic drug originally used for the treatment of narcotic addiction. In addition to use as a narcotic agonist, methadone is being used more frequently as a pain management agent. The psychological effects induced by using methadone are analgesia, sedation, and respiratory depression. Based on the saliva/plasma ratio calculated over salivary pH ranges of 6.4-7.6 for therapeutic or recreational doses of methadone, a cut-off <50 ng/mL is suggested. Due to this recommendation, the cut-off level of the methadone test was calibrated to 30 ng/mL.

MET: Methamphetamine is a potent stimulant chemically related to amphetamine but with greater CNS stimulation properties. The drug is often self-administered by nasal inhalation, smoking or oral ingestion.¹

OPI (MOP): The drug class opiates refers to any drug that is derived from the opium poppy, including naturally occurring compounds such as morphine and codeine and semi-synthetic drugs such as heroin. Opiates control pain by depressing the CNS, and demonstrate addictive properties when used for sustained periods of time. Opiates can be taken orally or by injection routes including intravenous, intramuscular and subcutaneous; illegal users may also take the intravenously or by nasal inhalation.³

*The window of detection varies for different opiates. Codeine can be detected within one hour and up to 7-21 hours after a single oral dose. Morphine is detectable for several days after a dose.

PPX: Propoxyphene or Dextropropoxyphene is a narcotic analgesic compound with a structural similarity to methadone. It is prescribed in the United States for the relief of moderate pain. Darvocet™, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Physiological effects of propoxyphene include respiratory depression. Propoxyphene is metabolized in the liver to yield norpropoxyphene. Norpropoxyphene has a longer half-life (30 to 36 hours) than that of propoxyphene (6 to 12 hours). Norpropoxyphene demonstrates substantially less central-nervous system depression than propoxyphene, but shows a greater local anesthetic effect.

CODEINE: Codeine is an opiate used to treat pain, as a cough medicine, and for diarrhea. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin or ibuprofen. Evidence does not support its use for acute cough suppression in children or adults. In Europe it is not recommended as a cough medicine in those under twelve years of age. It is generally taken by mouth. It typically starts working after half an hour with maximum effect at two hours. The total duration of its

effects last for about four to six hours. Common side effects include vomiting, constipation, itchiness, lightheadedness, and drowsiness. Serious side effects may include breathing difficulties and addiction. It is unclear if its use in pregnancy is safe. Care should be used during breastfeeding as it may result in opiate toxicity in the baby. Codeine works following being broken down by the liver into morphine.

This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) and gas chromatography/tandem mass spectrometry (GC/MS/MS) are the preferred confirmatory methods. Professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

PRINCIPLE

The InstaCube Oral Fluid Drug Test Cube is an immunoassay based on the principle of competitive binding. Drugs that may be present in the oral fluid specimen compete against their respective drug conjugate for binding sites on their specific antibody. During testing, a portion of the oral fluid specimen migrates along the test strip by capillary action. A drug, if present in the oral fluid specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration in the oral fluid specimen will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region. A drug-positive oral fluid specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative oral fluid specimen will generate a line in the test line region because of the absence of drug competition. To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

REAGENTS

The InstaCube Oral Fluid Drug Test Cube contains mouse monoclonal antibody-coupled particles and corresponding drug-protein conjugates. A goat antibody is employed in each control line.

PRECAUTIONS

- For employment and insurance use. For forensic use.
- Do not use after the expiration date.
- The test device should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used collector and device should be discarded according to local regulations.
- Safety data sheets available for professional user upon request

STORAGE AND STABILITY

Store as packaged in the sealed pouch either at room temperature or refrigerated (2-30°C). The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

The oral fluid specimen should be collected using the collector provided with the kit. Follow the detailed Directions for Use below. No other collection devices should be used with this test. Oral fluid collected at any time of the day may be used. If specimen cannot be tested immediately, it is recommended that specimen be stored at 2-8°C or -20°C for up to 72 hours. Specimen may also be stored at room temperature for up to 48 hours. For ideal shipment conditions, transport specimen using ice packs (2-8°C).

MATERIALS

Materials Provided

- Test devices
- Security seal labels
- Saliva collectors
- Package insert

Materials Required But Not Provided

- Timer
- Gloves


DIRECTIONS FOR USE

Allow the test device, specimen, and/or controls to reach room temperature (15-30°C) prior to testing. Instruct the donor to not place anything in the mouth including food, drink, gum, tobacco products for at least 10 minutes prior to collection.


1. Bring the pouch to room temperature before opening it. Remove the test device from the sealed pouch and use it as soon as possible.
2. Remove the collector from the sealed pouch, insert the sponge into the mouth. Close mouth and move the sponge around for oral fluid collection. Soak sponge (do no bite, suck or chew on the sponge), in oral fluid and swab the inside of the mouth and tongue. Collect oral fluid for **7 minutes** or until sponge is soft and fully saturated. **No hard spots should be felt on the sponge when saturated.** (See illustration 1)
3. Place the test device on a clean and flat surface. Remove the collection sponge from mouth and insert **gently** into the screening device, press until the collector cap is sealed with the device **tightly. Keep upright when inserting and pressing the sponge.** (See illustration 2)
4. **Keep Test device upright on flat surface and keep upright while test is running.** Wait for the colored signal to appear in test results area. Read the results at 10 minutes. Do not interpret results after 15 minutes.

Note: 1, Once the collection sponge locks in place, the device is airtight, tamper evident, and ready to be disposed or sent to lab for confirmation (on presumptive positive result).

2, In the case of no flowing even with enough saliva specimen, or the saliva is too thick to run, please move the device but don't tilt and keep upright back and forth on a flat and clean surface for several times until saliva flows up. Do not tilt the device when the test is running before reading results.



Interpretation results:



INTERPRETATION OF RESULTS

(Please refer to the previous illustration)

NEGATIVE: A colored line in the control line region (C) and a colored line in the test line region (T) for a specific drug indicate a negative result. This indicates that the drug concentration in the oral fluid specimen is below the designated cut-off level for that specific drug.

***NOTE:** The shade of color in the test line region (T) may vary, but it should be considered negative whenever there is even a faint colored line.

POSITIVE: A colored line in the control line region (C) but no line in the test line region (T) for a specific drug indicates a positive result. This indicates that the drug concentration in the oral fluid specimen exceeds the designated cut-off for that specific drug.

INVALID: Control line (C) fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test device. If the problem persists, discontinue using the lot immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A colored line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique. Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

1. The InstaCube Oral Fluid Drug Test Cube provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) or gas chromatography/tandem mass spectrometry (GC/MS/MS) is the preferred confirmatory method.
2. There is a possibility that technical or procedural errors, as well as other interfering substances in the oral fluid specimen may cause erroneous results.
3. A positive test result does not indicate the concentration of drug in the specimen or the route of administration.
4. A negative result may not necessarily indicate a drug-free specimen. Drug may be present in the specimen below the cut-off level of the test.
5. The test does not distinguish between drugs of abuse and certain medications.
6. A positive result may be obtained from certain foods or food supplements.

PERFORMANCE CHARACTERISTICS

Analytical Sensitivity

A phosphate-buffered saline (PBS) pool was spiked with drugs to target concentrations of $\pm 50\%$ cut-off and tested with the InstaCube Oral Fluid Drug Test Cube. The results are summarized below.

Drug Conc.	AMP 50		COC 20		BAR 50		THC 12		MTD 30		BZO 10	
(Cut-off range)	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0
Cut-off	15	15	14	16	14	16	16	14	14	16	15	15
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30
3X Cut-off	0	30	0	30	0	30	0	30	0	30	0	30

Drug Conc.	MOP		OPI		PPX		COD		MET	
(Cut-off range)	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0

-50% Cut-off	30	0	30	0	30	0	30	0	30	0
Cut-off	14	16	15	15	15	15	15	15	14	16
+50% Cut-off	0	30	0	30	0	30	0	30	0	30
3X Cut-off	0	30	0	30	0	30	0	30	0	30

Analytical Specificity

The following table lists the concentration of compounds (ng/mL) above which the InstaCube Oral Fluid Drug Test Cube identified positive results at 10 minutes.

AMPHETAMINE (AMP 50)		BENZODIAZEPINES (BZO 10)	
d-Amphetamine	50	Oxazepam	10
d,l-Amphetamine	125	Alprazolam	6
β -Phenylethylamine	4,000	Bromazepam	12
Tryptamine	1,500	Chlordiazepoxide	12
p-Hydroxyamphetamine	800	Clobazam	6
(+) 3,4-Methylenedioxamphetamine (MDA)	150	Clorazepate	25
l-Amphetamine	4,000	Delorazepam	25
BARBITURATE (BAR 50)		Desalkylflurazepam	25
Secobarbital	50	Diazepam	3
Amobarbital	100	Estazolam	3
Alphenal	100	Flunitrazepam	100
Aprobarbital	30	α -Hydroxyalprazolam	200
Butabarbital	30	(\pm)-Lorazepam	200
Butalbital	400	Midazolam	25
Butethal	30	Nitrazepam	12
Cyclopentobarbital	60	Norchlordiazepoxide	200
Pentobarbital	150	Nordiazepam	25
Phenobarbital	30	Temazepam	6
		Triazolam	25

COCAINE (COC 20)	
Benzoylcegonine	20
Cocaine	20
Cocaethylene	25
Ecgonine	1,500
Ecgoninemethylester	12,500
N-Acetylprocainamide	12,500
Chlordiazepoxide	12,500
MARIJUANA (THC 12)	
11-nor- Δ^9 -THC-9 COOH	12
Cannabinol	31,500
11-nor- Δ^8 -THC-9 COOH	2
Δ^8 -THC	6,000
Δ^9 -THC	20,000
METHADONE (MTD 30)	
Methadone	30
Doxylamine	50,00
Estrone-3-sulfate	50,00
Phencyclidine	50,00
METHAMPHETAMINE (MET 50)	
d-Methamphetamine	50
Fenfluramine	60,000
p-Hydroxymethamphetamine	400
Methoxyphenamine	25,000
3,4-Methylenedioxymethamphetamine (MDMA)	50

l-Phenylephrine	4,000
Procaine	2,000
(1R,2S)-(-) Ephedrine	400
1-Ephedrine	400
Mephentermine	800
(-)-Deoxyephedrine, L-Methamphetamine	3,000
Ephedrine	800
MORPHINE (MOP 15)	
Morphine	15
Codeine	15
Ethylmorphine	15
Hydromorphine	50
Hydrocodone	50
Morphine 3- β -d-glucuronide	30
Nalorphine	300
Oxymorphone	25,000
Thebaine	5,000
Diacetylmorphine (Heroin)	15
6-Monoacetylmorphine (6-MAM)	15
OPIATE (OPI 40)	
Morphine	40
Codeine	10
Ethylmorphine	24
Hydromorphine	100
Hydrocodone	100

Levorphanol	400
Oxycodone	25,000
Morphine 3- β -d-glucuronide	50
Norcodeine	1,500
Normorphine	12,500
Nalorphine	10,000
Oxymorphone	25,000
Thebaine	1,500
Diacetylmorphine (Heroin)	50
6-Monoacetylmorphine (6-MAM)	25
Bilirubin	3,500
PROPOXYPHENE (PPX 50)	
Propoxyphene (PPX)	50
D-Norpropoxyphene	200
CODEINE (COD 10)	
Codeine	10
Bilirubin	3,500
Ethylmorphine	24
Hydromorphine	100
Hydrocodone	100
Levorphanol	400
Oxycodone	25,000
Morphine 3- β -d-glucuronide	50
Norcodeine	1,500
Normorphine	12,500

Nalorphine	10,000
Oxymorphone	25,000
Thebaine	1,500
Diacetylmorphine (Heroin)	50
6-Monoacetylmorphine (6-MAM)	25
Morphine	40

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds spiked into drug-free PBS stock. The following compounds demonstrated no false positive results on the InstaCube Oral Fluid Drug Test Cube when tested at concentrations up to 100 μ g/mL.

Non Cross-Reacting Compounds

Acetaminophen	Labetalol
Acetophenetidine	Loperamide
Acetylsalicylic acid	Meprobamate
Aminopyrine	Methylphenidate
Amoxicillin	Nalidixic acid
Ampicillin	Naproxen
Amityryptiline	Niacinamide
Ascorbic acid	Nifedipine
Apomorphine	Nimesulide
Aspartame	Norethindrone
Atropine	Noscapine
Benzilic acid	d,l-Octopamine
Benzoic acid	Oxalic acid
Benzphetamine	Oxolinic acid
Caffeine	Oxymetazoline
Chloral hydrate	Papaverine
Chloramphenicol	Penicillin-G
Chlorothiazide	Pentazocine
d,l-Chloropheniramine	Perphenazine
Chlorpromazine	Phenelzine
Chloroquine	Trans-2-phenylcyclo-propylamine
Cholesterol	Phentermine
Clonidine	Phenylpropanolamine
Cortisone	Prednisolone
Creatinine	Phenolbarbital
Deoxycorticosterone	Prednisone
Dextromethorphan	d,l-Propranolol
Diclofenac	d-Pseudoephedrine
Dicyclomine	Quinacrine
Diflunisal	Quinine
Digoxin	Quindine
Diphenhydramine	Ranitidine
β -Estradiol	Salicylic acid
Ethyl-p-aminobenzoate	Sulfamethazine
l-Epinephrine	Sulindac
Erythromycin	Tetracycline
Fenoprofen	Tetrahydrocortisone3-acetate
Furosemide	Tetrahydrocortisone
Gentisic acid	3 (β -d-glucuronide)
Hemoglobin	Theophylline
Hydralazine	Thiamine
Hydrochlorothiazide	Thioridazine
Hydrocortisone	d,l-Tyrosine
o-Hydroxyhippuric acid	Tolbutamide
β Hydroxynorephedrine	Trazodone
5-Hydroxytryptamine	Triamterene
(Serotonin)	Trifluoperazine
3-Hydroxytyramine	Trimethoprim

Ibuprofen	d,l-Tryptophan
Iproniazid	Tyramine
(-)-Isoproterenol	Uric acid
Isoxsuprine	Verapamil
Ketoprofen	Zomepirac

BIBLIOGRAPHY

1. Moolchan E, *et al.* Saliva and Plasma Testing for Drugs of Abuse: Comparison of the Disposition and Pharmacological Effects of Cocaine. Addiction Research Center, IRP, NIDA, NIH, Baltimore, MD. As presented at the SOFT-TIAFT meeting October 1998.
2. Schramm W., *et al.* Drugs of Abuse in Saliva: A Review. *J Anal Tox*, 16 (1): 1-9, 1992.
3. Kim L, *et al.* Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. *ClinChem*, 48 (9): 1486-96, 2002.
4. Kang GI and Abbott FS. Analysis of methadone and metabolites in biological fluids with gas chromatography-mass spectrometry. *J Chromatogr.* 231 (2); 311-319. Sept 1982.

Manufactured for:

DTC

866-501-4292

www.prescreendrugtest.com